Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
20-23 May, 2025
Not Confirmed
Not Confirmed
21-23 May, 2025
Not Confirmed
Not Confirmed
21-23 May, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
20-23 May, 2025
Industry Trade Show
Not Confirmed
21-23 May, 2025
Industry Trade Show
Not Confirmed
21-23 May, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/us-drug-shortages-reduce-16-yoy-in-q1-2025-cns-drugs-antimicrobials-face-highest-scarcities
06 Mar 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/hanall-biopharma-announces-orphan-drug-designation-for-batoclimab-in-japan-for-active-thyroid-eye-disease-302393920.html
25 Nov 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/hanall-biopharma-daewoong-pharmaceutical-and-nurron-pharmaceuticals-announce-successful-completion-of-a-first-in-human-study-for-potential-disease-modifying-therapy-for-parkinsons-disease-302315158.html
01 Nov 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/hanall-biopharma-reports-q3-2024-financial-results-and-provides-business-update-302293804.html
26 Jul 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/hanall-biopharma-reports-q2-2024-financial-results-and-provides-business-update-302207336.html
15 Jul 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/hanall-biopharma-appoints-christopher-w-slavinsky-as-chief-business-development-and-legal-officer-302196473.html
28 May 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/hanall-biopharma-signs-licensing-agreement-with-turn-biotechnologies-to-develop-novel-treatments-for-eye-and-ear-diseases-302156468.html
ABOUT THIS PAGE
Hanall Biopharma is a supplier offers 2 products (APIs, Excipients or Intermediates).
Find a price of Cefoperazone Sodium bulk offered by Hanall Biopharma
Find a price of Fudosteine bulk offered by Hanall Biopharma